Viagra will endure, EU patent loss a mere dent
This article was originally published in Scrip
Viagra may have lost its patent in significant markets in Europe last week, but the treatment for erectile dysfunction is not about to flop out of the market. Experts forecast that the impact of the patent expiry will barely dent Pfizer's figures this year, and that it can be trusted to drive sales for the company for many years to come.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.